Product Code: ETC7733959 | Publication Date: Sep 2024 | Updated Date: Oct 2025 | Product Type: Market Research Report | |
Publisher: 6Wresearch | No. of Pages: 75 | No. of Figures: 35 | No. of Tables: 20 | |
The import shipments of cardioselective beta blockers to Japan in 2024 have seen a decline in concentration levels, with top exporting countries being the USA, Germany, Switzerland, Ireland, and Sweden. The low HHI concentration in 2023 decreased even further in 2024, indicating a competitive market landscape. The compound annual growth rate (CAGR) from 2020 to 2024 was -3.67%, with a slight improvement in the growth rate from 2023 to 2024 at -3.17%. These trends suggest a challenging market environment for cardioselective beta blockers importers in Japan.
1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 Japan Cardioselective Beta Blockers Market Overview |
3.1 Japan Country Macro Economic Indicators |
3.2 Japan Cardioselective Beta Blockers Market Revenues & Volume, 2021 & 2031F |
3.3 Japan Cardioselective Beta Blockers Market - Industry Life Cycle |
3.4 Japan Cardioselective Beta Blockers Market - Porter's Five Forces |
3.5 Japan Cardioselective Beta Blockers Market Revenues & Volume Share, By Indication, 2021 & 2031F |
3.6 Japan Cardioselective Beta Blockers Market Revenues & Volume Share, By Target, 2021 & 2031F |
3.7 Japan Cardioselective Beta Blockers Market Revenues & Volume Share, By Drugs, 2021 & 2031F |
3.8 Japan Cardioselective Beta Blockers Market Revenues & Volume Share, By Route of Administration, 2021 & 2031F |
4 Japan Cardioselective Beta Blockers Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.2.1 Increasing prevalence of cardiovascular diseases in Japan |
4.2.2 Growing awareness about the benefits of using cardioselective beta blockers |
4.2.3 Rising healthcare expenditure and investment in cardiovascular treatments |
4.3 Market Restraints |
4.3.1 Stringent regulatory requirements for drug approval in Japan |
4.3.2 Competition from alternative treatments such as calcium channel blockers |
4.3.3 Potential side effects associated with the long-term use of beta blockers |
5 Japan Cardioselective Beta Blockers Market Trends |
6 Japan Cardioselective Beta Blockers Market, By Types |
6.1 Japan Cardioselective Beta Blockers Market, By Indication |
6.1.1 Overview and Analysis |
6.1.2 Japan Cardioselective Beta Blockers Market Revenues & Volume, By Indication, 2021- 2031F |
6.1.3 Japan Cardioselective Beta Blockers Market Revenues & Volume, By Angina, 2021- 2031F |
6.1.4 Japan Cardioselective Beta Blockers Market Revenues & Volume, By Hypertension, 2021- 2031F |
6.1.5 Japan Cardioselective Beta Blockers Market Revenues & Volume, By Heart Failure, 2021- 2031F |
6.1.6 Japan Cardioselective Beta Blockers Market Revenues & Volume, By Arrhythmias, 2021- 2031F |
6.1.7 Japan Cardioselective Beta Blockers Market Revenues & Volume, By Others, 2021- 2031F |
6.2 Japan Cardioselective Beta Blockers Market, By Target |
6.2.1 Overview and Analysis |
6.2.2 Japan Cardioselective Beta Blockers Market Revenues & Volume, By Beta-1 Receptors, 2021- 2031F |
6.2.3 Japan Cardioselective Beta Blockers Market Revenues & Volume, By Beta-2 Receptors, 2021- 2031F |
6.2.4 Japan Cardioselective Beta Blockers Market Revenues & Volume, By Others, 2021- 2031F |
6.3 Japan Cardioselective Beta Blockers Market, By Drugs |
6.3.1 Overview and Analysis |
6.3.2 Japan Cardioselective Beta Blockers Market Revenues & Volume, By Betaxolol, 2021- 2031F |
6.3.3 Japan Cardioselective Beta Blockers Market Revenues & Volume, By Acebutolol, 2021- 2031F |
6.3.4 Japan Cardioselective Beta Blockers Market Revenues & Volume, By Esmolol, 2021- 2031F |
6.3.5 Japan Cardioselective Beta Blockers Market Revenues & Volume, By Atenolol, 2021- 2031F |
6.3.6 Japan Cardioselective Beta Blockers Market Revenues & Volume, By Others, 2021- 2031F |
6.4 Japan Cardioselective Beta Blockers Market, By Route of Administration |
6.4.1 Overview and Analysis |
6.4.2 Japan Cardioselective Beta Blockers Market Revenues & Volume, By Oral, 2021- 2031F |
6.4.3 Japan Cardioselective Beta Blockers Market Revenues & Volume, By Parenteral, 2021- 2031F |
6.4.4 Japan Cardioselective Beta Blockers Market Revenues & Volume, By Others, 2021- 2031F |
7 Japan Cardioselective Beta Blockers Market Import-Export Trade Statistics |
7.1 Japan Cardioselective Beta Blockers Market Export to Major Countries |
7.2 Japan Cardioselective Beta Blockers Market Imports from Major Countries |
8 Japan Cardioselective Beta Blockers Market Key Performance Indicators |
8.1 Patient adherence rate to cardioselective beta blockers treatment |
8.2 Number of clinical trials and research studies on cardioselective beta blockers in Japan |
8.3 Prescription rate of cardioselective beta blockers by healthcare providers |
9 Japan Cardioselective Beta Blockers Market - Opportunity Assessment |
9.1 Japan Cardioselective Beta Blockers Market Opportunity Assessment, By Indication, 2021 & 2031F |
9.2 Japan Cardioselective Beta Blockers Market Opportunity Assessment, By Target, 2021 & 2031F |
9.3 Japan Cardioselective Beta Blockers Market Opportunity Assessment, By Drugs, 2021 & 2031F |
9.4 Japan Cardioselective Beta Blockers Market Opportunity Assessment, By Route of Administration, 2021 & 2031F |
10 Japan Cardioselective Beta Blockers Market - Competitive Landscape |
10.1 Japan Cardioselective Beta Blockers Market Revenue Share, By Companies, 2024 |
10.2 Japan Cardioselective Beta Blockers Market Competitive Benchmarking, By Operating and Technical Parameters |
11 Company Profiles |
12 Recommendations |
13 Disclaimer |